Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Dis Markers ; 2020: 2696317, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-31998415

RESUMO

Introduction. Exhaled breath condensate (EBC) is a noninvasive method to collect samples from the respiratory tract. Usually, a thermoelectric cooling module is required to collect sufficient EBC volume for analyses. In here, we assessed the feasibility of cytokine and chemokine detection in EBC collected directly from the ventilator circuit without the use of a cooling module: swivel-derived exhaled breath condensate (SEBC). METHODS: SEBC was prospectively collected from the swivel adapter and stored at -80°C. The objective of this study was to detect cytokines and chemokines in SEBC with a multiplex immunoassay. Secondary outcomes were to assess the correlation between cytokine and chemokine concentrations in SEBC and mechanical ventilation parameters, systemic inflammation parameters, and hemodynamic parameters. RESULTS: Twenty-nine SEBC samples were obtained from 13 ICU patients. IL-1ß, IL-4, IL-8, and IL-17 were detected in more than 90% of SEBC samples, and significant correlations between multiple cytokines and chemokines were found. Several significant correlations were found between cytokines and chemokines in SEBC and mechanical ventilation parameters and serum lactate concentrations. CONCLUSION: This pilot study showed that it is feasible to detect cytokines and chemokines in SEBC samples obtained without a cooling module. Despite small sample size, correlations were found between cytokines and chemokines in SEBC and mechanical ventilation parameters, as well as serum lactate concentrations. This simple SEBC collection method provides the opportunity to collect EBC samples in large prospective ICU cohorts.


Assuntos
Quimiocinas/análise , Interleucinas/análise , Síndrome do Desconforto Respiratório/diagnóstico , Adulto , Idoso , Biomarcadores/análise , Testes Respiratórios/instrumentação , Testes Respiratórios/métodos , Feminino , Humanos , Imunoensaio/métodos , Masculino , Pessoa de Meia-Idade , Síndrome do Desconforto Respiratório/terapia , Ventiladores Mecânicos
4.
Crit Care Med ; 43(12): 2582-8, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26448616

RESUMO

OBJECTIVE: To quantify antibiotic-associated within-host antibiotic resistance acquisition rates in Pseudomonas aeruginosa, Klebsiella species, and Enterobacter species from lower respiratory tract samples of ICU patients receiving selective digestive decontamination, selective oropharyngeal decontamination, or standard care. DESIGN: Prospective cohort. SETTING: This study was nested within a cluster-randomized crossover study of selective digestive decontamination and selective oropharyngeal decontamination in 16 ICUs in The Netherlands. PATIENTS: Eligible patients were those colonized in the respiratory tract with P. aeruginosa, Klebsiella species, or Enterobacter species susceptible to one of the marker antibiotics and with at least two subsequent microbiological culture results from respiratory tract samples available. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Antibiotic resistance acquisition rates were defined as the number of conversions from susceptible to resistant for a specific antibiotic per 100 patient-days or 100 days of antibiotic exposure within an individual patient. The hazard of antibiotic use for resistance development in P. aeruginosa was based on time-dependent Cox regression analysis. Findings of this study cohort were compared with those of a previous cohort of patients not receiving selective digestive decontamination/selective oropharyngeal decontamination. Numbers of eligible patients were 277 for P. aeruginosa, 174 for Klebsiella species, and 106 for Enterobacter species. Resistance acquisition rates per 100 patient-days ranged from 0.2 (for colistin and ceftazidime in P. aeruginosa and for carbapenems in Klebsiella species) to 3.0 (for piperacillin-tazobactam in P. aeruginosa and Enterobacter species). For P. aeruginosa, the acquisition rates per 100 days of antibiotic exposure ranged from 1.4 for colistin to 4.9 for piperacillin-tazobactam. Acquisition rates were comparable for patients receiving selective digestive decontamination/selective oropharyngeal decontamination and those receiving standard care. Carbapenem exposure had the strongest association with resistance development (adjusted hazard ratio, 4.2; 95% CI, 1.1-15.6). CONCLUSION: Within-host antibiotic resistance acquisition rates for systemically administered antibiotics were comparable between patients receiving selective decontamination and those receiving standard care and were highest during carbapenem use.


Assuntos
Antibacterianos/administração & dosagem , Antibacterianos/farmacologia , Farmacorresistência Bacteriana/efeitos dos fármacos , Bactérias Gram-Negativas/efeitos dos fármacos , Unidades de Terapia Intensiva/organização & administração , Infecções Respiratórias/prevenção & controle , Cuidados Críticos , Estudos Cross-Over , Enterobacter/efeitos dos fármacos , Trato Gastrointestinal/efeitos dos fármacos , Trato Gastrointestinal/microbiologia , Humanos , Klebsiella/efeitos dos fármacos , Países Baixos/epidemiologia , Orofaringe/efeitos dos fármacos , Orofaringe/microbiologia , Estudos Prospectivos , Pseudomonas aeruginosa/efeitos dos fármacos , Infecções Respiratórias/microbiologia
5.
JAMA ; 312(14): 1429-1437, 2014 10 08.
Artigo em Inglês | MEDLINE | ID: mdl-25271544

RESUMO

IMPORTANCE: Selective decontamination of the digestive tract (SDD) and selective oropharyngeal decontamination (SOD) are prophylactic antibiotic regimens used in intensive care units (ICUs) and associated with improved patient outcome. Controversy exists regarding the relative effects of both measures on patient outcome and antibiotic resistance. OBJECTIVE: To compare the effects of SDD and SOD, applied as unit-wide interventions, on antibiotic resistance and patient outcome. DESIGN, SETTING, AND PARTICIPANTS: Pragmatic, cluster randomized crossover trial comparing 12 months of SOD with 12 months of SDD in 16 Dutch ICUs between August 1, 2009, and February 1, 2013. Patients with an expected length of ICU stay longer than 48 hours were eligible to receive the regimens, and 5881 and 6116 patients were included in the clinical outcome analysis for SOD and SDD, respectively. INTERVENTIONS: Intensive care units were randomized to administer either SDD or SOD. MAIN OUTCOMES AND MEASURES: Unit-wide prevalence of antibiotic-resistant gram-negative bacteria. Secondary outcomes were day-28 mortality, ICU-acquired bacteremia, and length of ICU stay. RESULTS: In point-prevalence surveys, prevalences of antibiotic-resistant gram-negative bacteria in perianal swabs were significantly lower during SDD compared with SOD; for aminoglycoside resistance, average prevalence was 5.6% (95% CI, 4.6%-6.7%) during SDD and 11.8% (95% CI, 10.3%-13.2%) during SOD (P < .001). During both interventions the prevalence of rectal carriage of aminoglycoside-resistant gram-negative bacteria increased 7% per month (95% CI, 1%-13%) during SDD (P = .02) and 4% per month (95% CI, 0%-8%) during SOD (P = .046; P = .40 for difference). Day 28-mortality was 25.4% and 24.1% during SOD and SDD, respectively (adjusted odds ratio, 0.96 [95% CI, 0.88-1.06]; P = .42), and there were no statistically significant differences in other outcome parameters or between surgical and nonsurgical patients. Intensive care unit-acquired bacteremia occurred in 5.9% and 4.6% of the patients during SOD and SDD, respectively (odds ratio, 0.77 [95% CI, 0.65-0.91]; P = .002; number needed to treat, 77). CONCLUSIONS AND RELEVANCE: Unit-wide application of SDD and SOD was associated with low levels of antibiotic resistance and no differences in day-28 mortality. Compared with SOD, SDD was associated with lower rectal carriage of antibiotic-resistant gram-negative bacteria and ICU-acquired bacteremia but a more pronounced gradual increase in aminoglycoside-resistant gram-negative bacteria. TRIAL REGISTRATION: trialregister.nlIdentifier: NTR1780.


Assuntos
Antibacterianos/uso terapêutico , Trato Gastrointestinal/microbiologia , Infecções por Bactérias Gram-Negativas/prevenção & controle , Unidades de Terapia Intensiva/estatística & dados numéricos , Orofaringe/microbiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Bacteriemia , Infecção Hospitalar/prevenção & controle , Estudos Cross-Over , Farmacorresistência Bacteriana , Feminino , Humanos , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Reto/microbiologia , Análise de Sobrevida , Resultado do Tratamento , Adulto Jovem
7.
Crit Care Med ; 30(4): 841-5, 2002 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11940756

RESUMO

OBJECTIVE: We studied the activity of a single oral dose of RWJ-67657, a synthetic p38 mitogen-activated protein kinase inhibitor, in preventing dual leukocyte/endothelial activation after endotoxin infusion in healthy volunteers. DESIGN: Prospective placebo-controlled study. SETTING: Intensive care unit at a university medical center. SUBJECTS: Twenty-one healthy male volunteers. INTERVENTIONS: Endotoxin (4 ng/kg) as a 1-min infusion. According to randomization, the volunteers received placebo (n = 6) or 1400 mg (n = 4), 700 mg (n = 6), or 350 mg (n = 5) of RWJ-67657. MEASUREMENTS AND MAIN RESULTS: Neutrophil activation was investigated by analyzing the extent of membrane expression of adhesion markers by calibrated flow cytometry. Circulating intercellular adhesion molecule-1 and E-selectin were measured by enzyme-linked immunosorbent assays. The endotoxin-induced shedding of L-selectin was diminished in a dose-dependent manner (p <.0001). High-dose RWJ-67657 prevented up-regulation of the integrins CD11b (p <.01) and CD 66b (p <.01) on neutrophils. The endotoxin-induced increase in circulating intercellular adhesion molecule-1 and circulation E-selectin was almost completely prevented by high-dose RWJ-67657. CONCLUSION: A single oral dose of RWJ-67657 prevented neutrophil and endothelial activation after endotoxin infusion.


Assuntos
Endotélio/efeitos dos fármacos , Endotoxinas/administração & dosagem , Inibidores Enzimáticos/farmacologia , Imidazóis/administração & dosagem , Proteínas Quinases Ativadas por Mitógeno/antagonistas & inibidores , Ativação de Neutrófilo/efeitos dos fármacos , Piridinas/administração & dosagem , Adulto , Relação Dose-Resposta a Droga , Selectina E/análise , Citometria de Fluxo , Humanos , Molécula 1 de Adesão Intercelular/análise , Selectina L/análise , Masculino , Estudos Prospectivos , Proteínas Quinases p38 Ativadas por Mitógeno
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...